The identity of the first 10 medicines that will be subject to the first round of Medicare pricing negotiations has been revealed and, as expected, some big brands are in
The Centers for Medicare and Medicaid Services (CMS) has made some minor changes to its plan to allow Medicare to negotiate some drug prices after a series of lawsuits fro
The Centers for Medicare and Medicaid Services (CMS) in the US has provided more details about the controversial plan to require participation in a patient registry as a c
Legal challenges to Medicare’s price negotiation initiative introduced in the Inflation Reduction Act (IRA) continue to emerge, with pharmaceutical trade organisation PhRM
Bristol-Myers Squibb has filed a lawsuit against the US government that aims to block the drug price negotiation elements of the Inflation Reduction Act (IRA), joining fel
In a new update, the US government has more than doubled the size of the latest list of medicines subject to enforced rebates if their prices rise higher than inflation.
While at Reuters Pharma Europe in Barcelona the other week, pharmaphorum web editor Nicole Raleigh spoke with Florian Schnappauf, VP of enterprise commercial strategy at Veeva Europe, about
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.